A study found that for the assessment of clinical outcomes based on the detection of common BRAF, KRAS, and EGFR mutations, sEV nucleic acids are more sensitive that plasma ctDNA in patients with NSCLC [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.